阿替利珠单抗联合化疗治疗卵巢癌的效果及对肿瘤标志物、短期预后的影响

Effect of atezolizumab combined with chemotherapy on ovarian cancer and its influence on tumor markers and short-term prognosis

目的 观察阿替利珠单抗联合化疗治疗卵巢癌(OC)的效果及对肿瘤标志物、短期预后的影响。方法 选取衡水市第二人民医院2020年9月至2022年9月收治的100例OC患者为研究对象,按照治疗方法不同分为化疗组、T药组各50例。化疗组接受常规静脉化疗,T药组在化疗基础上联合阿替利珠单抗治疗。比较治疗6个周期后两组患者的近期疗效和不良反应的发生情况,对比治疗前、治疗6个周期后两组肿瘤标志物[糖抗原125(CA125)、人附睾蛋白4(HE4)],并观察两组的短期预后。结果 治疗6个周期后,T药组疗效及治疗有效率高于化疗组(P <0.05);T药组治疗期间不良反应发生率低于化疗组(P <0.05);两组CA125、HE4水平较治疗前均有降低(P <0.05),且T药组低于化疗组(P <0.05)。两组治疗后6个月复发率比较差异无统计学意义(P>0.05),T药组治疗后12个月复发率低于化疗组(P <0.05)。结论 阿替利珠单抗联合化疗治疗OC具有显著疗效,能减少化疗期间不良反应的发生,同时能降低患者肿瘤标志物水平,有利于患者的短期预后。

Objective To observe the effect of atezolizumab combined with chemotherapy in the treatment of ovarian cancer(OC) and its influence on tumor markers and short-term prognosis.Methods A total of 100 patients with OC admitted to the Second People's Hospital of Hengshui from September 2020 to September 2022 were selected as research subjects,and were divided into chemotherapy group and atezolizumab group with 50 cases in each group according to the different treatment methods.The chemotherapy group received conventional intravenous chemotherapy,and the atezolizumab group received chemotherapy combined with atezolizumab.The short-term efficacy and occurrence of adverse reactions after 6 cycles of treatment and tumor markers [carbohydrate antigen 125(CA125),human epididymal protein 4(HE4)] before treatment and after 6 cycles of treatment were compared between the two groups,and the short-term prognosis was observed in the two groups.Results After 6 cycles of treatment,the efficacy and effective rate of treatment in atezolizumab group were higher than those in chemotherapy group(P < 0.05).During treatment,the incidence rates of adverse reactions were lower in atezolizumab group than those in chemotherapy group(P < 0.05).The CA125 and HE4 levels in both groups decreased compared with those before treatment(P < 0.05),and the levels in atezolizumab group were lower than those in chemotherapy group(P < 0.05).There was no statistical difference in the recurrence rate at 6 months after treatment between the two groups(P > 0.05),and the recurrence rate at 12 months after treatment in atezolizumab group was lower than that in chemotherapy group(P < 0.05).Conclusion Atezolizumab combined with chemotherapy has significant efficacy in the treatment of OC,and it can reduce the occurrence of adverse reactions during chemotherapy,and reduce the levels of tumor markers,which is beneficial to the short-term prognosis of patients.